No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
OTLK Outlook Therapeutics
- 7.070
- -0.490-6.48%
Close Jun 18 16:00 ET
- 7.310
- +0.240+3.39%
Post 19:11 ET
165.48MMarket Cap-593P/E (TTM)
7.840High7.054Low160.11KVolume7.580Open7.560Pre Close1.16MTurnover1.36%Turnover RatioLossP/E (Static)23.41MShares36.99852wk High-1.23P/B83.22MFloat Cap4.00452wk Low--Dividend TTM11.77MShs Float219.200Historical High--Div YieldTTM10.40%Amplitude4.004Historical Low7.271Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) Largest Shareholders Are Individual Investors With 31% Ownership, Private Equity Firms Own 31%
Outlook Therapeutics(R) (NASDAQ: OTLK) to Participate Virtual Investor Closing Bell Series
Outlook Therapeutics to Present at the Virtual Investor Pitch Conference
Outlook Therapeutics(R) (NASDAQ:OTLK) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team
Watch the "What This Means" video hereOutlook CEO, Russ Trenary underscores that LYTENAVA (bevacizumab gamma) has become the first ophthalmic formulation of bevacizumab to receive European Commission
Buy Rating Justified by Outlook Therapeutics' Advancements and Market Prospects
Express News | Outlook Therapeutics Gains Marketing Authorization From European Commission For LYTENAVA To Treat Retina Diseases
Comments
$Outlook Therapeutics(OTLK.US$
Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
Outlook Therapeutics has received European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma), an ophthalmic formulation for treating wet AMD. This makes it the first ophthalmic bevacizumab formulation approved for wet AMD in the EU. This authorization covers all 27 EU Member States and will extend to Icela...
Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
Outlook Therapeutics has received European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma), an ophthalmic formulation for treating wet AMD. This makes it the first ophthalmic bevacizumab formulation approved for wet AMD in the EU. This authorization covers all 27 EU Member States and will extend to Icela...
$Outlook Therapeutics(OTLK.US$ Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (Maa) for Ons-5010 as a Treatment for Wet AMD
$Outlook Therapeutics(OTLK.US$ Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million
4
2
$Outlook Therapeutics(OTLK.US$ Just keep slowly walking up up up! been a nice uptrend for a few days now!
1
$Outlook Therapeutics(OTLK.US$ BTIG Upgrades Outlook Therapeutics to Buy, Announces $50 Price Target
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg